0.7247  0.022 (3.13%)		11-02 16:00
Open: 0.72 High: 0.7465 Volume: 5,712,710		Pre. Close: 0.7027 Low: 0.7046 Market Cap: 246(M)

Short term
Mid term
Targets	6-month :	1.11	1-year :	1.3
Resists	First :	0.95	Second :	1.12
Pivot price	0.77
Supports	First :	0.69	Second :	0.57
MAs	MA(5) :	0.74	MA(20) :	0.83
	MA(100) :	1.18	MA(250) :	1.41
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	11.2	D(3) :	14.5
RSI	RSI(14): 32.9
52-week	High :	2.72	Low :	0.69

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ OCGN ] has closed above bottom band by 24.5%. Bollinger Bands are 37.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	0.76 - 0.77	0.77 - 0.77
Low:	0.68 - 0.69	0.69 - 0.69
Close:	0.7 - 0.7	0.7 - 0.71

Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis. OCU410: Another gene therapy candidate, currently being developed to address dry age-related macular degeneration (AMD). OCU200: A novel fusion protein, presently undergoing preclinical evaluation for its potential in treating diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen maintains significant strategic collaborations, including a partnership with CanSino Biologics Inc. for the joint development and manufacturing of gene therapies, and an alliance with Bharat Biotech for the commercialization of COVAXIN within the United States market. The company's corporate headquarters are situated in Malvern, Pennsylvania.

Fri, 30 Oct 2026
Ocugen, Inc. (OCGN) Seasonal Returns Chart - Yahoo! Finance Canada

Fri, 30 Oct 2026
Ocugen, Inc. (OCGN) Seasonal returns chart - Yahoo Finance Australia

Fri, 23 Oct 2026
Ocugen, Inc. Estimates – NASDAQ:OCGN - TradingView

Fri, 25 Sep 2026
Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa - Ocugen, Inc.

Tue, 01 Sep 2026
Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration - Ocugen, Inc.

Thu, 06 Aug 2026
Ocugen Inc (OCGN) (Q2 2026) Earnings Call Highlights: FDA Clearance for OCU410 Phase 3 Trial ... - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	339 (M)
Held by Insiders	3.343e+008 (%)
Held by Institutions	1.3 (%)
Shares Short	98,310 (K)
Shares Short P.Month	0 (K)

EPS	-6.717e+007
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	-1 %
Return on Assets (ttm)	105.1 %
Return on Equity (ttm)	-48.5 %
Qtrly Rev. Growth	4.58e+006 %
Gross Profit (p.s.)	3.7
Sales Per Share	0
EBITDA (p.s.)	-1.72599e+007
Qtrly Earnings Growth	-0.3 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-61 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	-33.11

Dividend	0
Forward Dividend	1.0205e+008
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.